Compare Manulife Financial Corporation (MFC) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Smith & Nephew plc — how do they compare? Manulife Financial Corporation trades at $42.8 (market cap $69.96B), while Smith & Nephew plc trades at $30.09 (market cap $12.64B). The key difference: Manulife Financial Corporation is far larger — about 5.5× Smith & Nephew plc's market cap, and Manulife Financial Corporation pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| MFC | SNN | |
|---|---|---|
Market Cap | $69.96B | $12.64B |
Sector | Financials | Health |
52-Week High | $43.39 | $38.70 |
52-Week Low | $29.90 | $28.73 |
Enterprise Value | $66.52B | $15.41B |
Dividend Yield | 3.14% | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $42.56, down 1.91% today but remains near 52-week highs. The stock shows strong fundamentals with revenue growth from $46.2B in 2024 to $53.0B in 2025 and consistent profitability (12.07% net margin). Technical indicators are mixed with bullish moving averages but overbought RSI levels. Recent Q1 2026 earnings missed expectations despite strong Asia performance, while analyst consensus remains bullish with 57% buy ratings.
MFC presents a compelling value case with reasonable valuation (P/E 17.75) and dividend yield support. Key opportunities include AI integration partnerships and Asia growth, though risks include wealth management outflows and regulatory scrutiny. The stock's current technical overbought condition suggests potential near-term consolidation before resuming upward trajectory.
Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.
SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
